In a world-first, an early phase trial of an mRNA personalised cancer vaccine has shown promising results for preventing melanoma recurrence in patients with resected high-risk melanoma (stage III and IV).
Read more about the five MIA researchers named on the Clarivate list of Highly Cited Researchers 2022.
Read more about the Cancer Institute NSW Awards and the highly cited immunotherapy publication.
Tailoring skin checks based on personal risk, the impact of adjuvant and neo-adjuvant therapies, and the latest in personalised immunotherapy for advanced patients are amongst a plethora of research advances.
Diets low in fibre and omega-3 fatty acids linked to poorer response to immunotherapy.
Researchers and clinicians from Melanoma Institute Australia have played a leading role at the recent ESMO Congress in Paris.
Prof Long has been named No 1 Melanoma Expert in worldwide rankings just released by expertscape, based on articles published 2012-2022.
New clinical tool developed by Melanoma Institute Australia hailed a breakthrough in personalising treatment for all cancer patients.
An unprecedented number of breakthroughs to be presented by MIA researchers at world's leading clinical oncology conference.
Immunotherapy after surgery proven effective in reducing disease spread in high risk early stage patients.
